Using CRISPR to Modulate Gene Expression
RARECast - Un podcast de RARECast - Les jeudis
Catégories:
Amber Salzman, CEO of Epicrispr Biotechnologies, discusses the company’s one-and-done therapies work to target the epigenome, its lead program in FSHD, and the broader applications for its therapeutic approach.
